OakChart

Quanterix Corp

QTRXHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.02-0.26 (-7.93%)
2026-11-12 05:39 CET
Market cap
142.83 USD m
Revenue, TTM
148.15 USD m
Net income, TTM
-111.18 USD m
Free cash flow, TTM
-56.03 USD m
EPS diluted, TTM
-2.36
P/E
-
Compare

Price

QTRX against its 20, 50 and 200-day averages
2050200miss
2.003.004.005.003.0M6.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26QTRXclose 3.0220-day 2.9550-day 3.04200-day 3.713.0252w low

65.6% under the 52-week high of 8.77 on 9 Jan 2026. 52-week low 2.15 on 10 Aug 2026. Last 15 sessions, 30.3% high to low

Volume 0.72× normal · the line is the 50-bar volume average

Profile

QTRX
52-week range, 13% of the way up
2.158.77

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

IndexRUT
Employees450
IPODec 07, 2017
Beta1.00
ATR, 14d0.26
Rel volume0.72
Short float10.89%
Insider own11.73%
Inst own61.29%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap143.39M
Enterprise Value97.39M
Income-111.18M
Sales148.15M
Book/sh4.62
Cash/sh1.63
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees450
IPODec 07, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S0.97
P/B0.65
P/C1.85
P/FCF-
EV/EBITDA-
EV/Sales0.66
Quick Ratio2.22
Current Ratio3.09
Debt/Eq0.14
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.36
EPS next Y-1.44
EPS next Q-0.37
EPS this Y9.36%
EPS next Y36.66%
EPS next 5Y25.77%
EPS past 3/5Y2.27% -18.72%
Sales past 3/5Y9.59% 9.97%
EPS Y/Y TTM-1.29%
Sales Y/Y TTM13.78%
EPS Q/Q37.39%
Sales Q/Q-13.07%
EarningsNov 09 BMO
EPS/Sales Surpr.-9.52% 3.31%

Ownership

Insider Own11.73%
Insider Trans1.89%
Inst Own61.29%
Inst Trans-16.85%
ROA-29.86%
ROE-41.65%
ROIC-45.70%
Gross Margin41.70%
Oper. Margin-60.90%
Profit Margin-75.05%
SMA202.49%
SMA50-0.53%
SMA200-18.51%
Trades-

Technical

Shs Outstand47.45M
Shs Float41.91M
Short Float10.89%
Short Ratio6.45
Short Interest4.56M
52W High8.77 -65.56%
52W Low2.15 40.47%
Volatility12.57% 7.85%
ATR (14)0.26
RSI (14)49.61
Beta1.00
Rel Volume0.72
Avg Volume707.41K
Volume507,098

Performance

Perf Week-0.66%
Perf Month-4.13%
Perf Quarter5.59%
Perf Half Y4.86%
Perf YTD-52.52%
Perf Year-39.60%
Perf 3Y-85.27%
Perf 5Y-94.50%
Perf 10Y-
Recom3.00
Target Price3.33
Prev Close3.28
Price3.02
Change %-7.93%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Aug 11, 2025DowngradeCCanaccord GenuityBuy → Hold$5+65.6%
Feb 01, 2024InitiatedBScotiabankSector Outperform$30+893.4%
Sep 25, 2023UpgradeCCanaccord GenuityHold → Buy$25 → $32+959.6%
Aug 08, 2023UpgradeSSVB SecuritiesMarket Perform → Outperform$30+893.4%
May 23, 2023UpgradeGGoldmanNeutral → Buy$13 → $27+794.0%
Aug 15, 2022DowngradeCCanaccord GenuityBuy → Hold$40 → $12+297.4%
Aug 09, 2022DowngradeSSVB LeerinkOutperform → Mkt Perform$35 → $15+396.7%
Aug 09, 2022DowngradeCCowenOutperform → Market Perform$38 → $18+496.0%
Mar 02, 2022UpgradeGGoldmanSell → Neutral$40+1,224.5%
Oct 15, 2021ResumedCCowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
ALMRAlamar Biosciences Inc2.20B
QSIQuantum-Si Incorporated279.07M
LABStandard BioTools Inc253.85M
NAUTNautilus Biotechnology Inc308.24M
SEERSeer Inc88.04M
TXG10x Genomics Inc8.08B
CTKBCytek BioSciences Inc753.32M
MASS908 Devices Inc415.82M
PACBPacific Biosciences of California Inc654.02M
BIOBio-Rad Laboratories Inc10.39B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DONNELLY WILLIAM PDirectorAug 13 '26Buy2.9372,245211,67899,400Aug 14 04:01 PM
DONNELLY WILLIAM PDirectorAug 12 '26Buy2.7527,15574,67627,155Aug 14 04:01 PM
Meadows BenjaminChief Commercial OfficerMay 12 '26Buy2.773,5009,6953,500Jun 12 05:32 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Quanterix Posts Its First Sequential Growth Of The Turnaround, But Rising Cash Burn And A Hazier FDA Timeline Undercut The Proof Point (Earnings Whispers) +16.75%
  • Quanterix Releases Financial Results for the Third Quarter of 2026 (Business Wire)
  • Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 (Business Wire) +7.96%
  • Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals (Business Wire)
  • Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026 (Business Wire)
  • Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.99% +7.22%
  • Quanterix Names Dr. Yuri Fesko Chief Medical Officer (Business Wire)
  • Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ... (GuruFocus.com) -39.95% +8.47%
  • Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even (InvestorsHub)
  • Quanterix Names Jim Gute Chief Commercial Officer (Business Wire)
  • Quanterix Releases Financial Results for the Second Quarter of 2026 (Business Wire)
  • Earnings To Watch: Quanterix Corp (QTRX) Q2 2026 -- GF Value Sees 253% Upside (GuruFocus.com) +5.22%
  • Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12 (Business Wire)
  • Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026 (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.460-0.420-1.04034.9733.853
2026Q22026-08-10-1.040-0.410-1.03832.9137.483
2026Q12026-05-06-0.370-0.513-0.37336.4236.843
2025Q42026-03-02-0.490-0.449-0.49443.8638.214
2025Q32025-11-10-0.730-0.458-0.72840.2337.684
2025Q22025-08-07-0.770-0.423-0.77224.4828.234
2025Q12025-05-12-0.530-0.435-0.53030.3328.216
2024Q42025-03-17-0.300-0.255-0.30235.1634.906
2024Q32024-11-12-0.211-0.244-0.21735.7034.146
2024Q22024-08-08-0.250-0.266-0.19334.3833.736
2024Q12024-05-07-0.260-0.309-0.29332.0731.485
2023Q42024-02-29-0.330-0.314-0.23331.5529.855
2023Q32023-11-06-0.210-0.368-0.20631.3327.614
2023Q22023-08-07-0.160-0.378-0.16231.0325.894
2023Q12023-05-09-0.160-0.382-0.16428.4625.404
2022Q42023-03-06-0.500-0.468-0.50125.8225.784

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.592-1.662-1.62656.7355.07
2020FY-1.102-1.219-1.06668.8074.82
2021FY-1.602-1.705-1.603105.3104.58
2022FY-2.610-2.580-2.692105.52105.49
2023FY-0.860-0.818-0.754122.37120.68
2024FY-1.000-0.946-1.004137.42137.2
2025FY-2.510-2.268-2.510138.9133.16
2026FY--2.275--143.2
2027FY--1.441--156.31
2028FY--1.027--179.44
2029FY--0.595--204.1
2030FY--0.670--236.1

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0931238.9038.4339.80
2026Q4S2026-10-2631040.1939.1041.67
2026Q4S2026-10-2431140.1939.1041.67
2026Q4S2026-10-1631240.1939.1041.67
2026Q4S2026-10-0931240.2039.1041.70
2026Q4S2026-08-1430339.8037.9041.70
2026Q4S2026-08-1230339.7937.9041.67
2026Q4S2026-08-1031242.6037.9050.11
2026Q4S2026-08-0731050.7650.0752.10
2026Q4S2026-07-2131050.7650.0752.10
2026Q4S2026-07-1033050.7650.0752.10
2026Q4S2026-05-1732050.3248.8052.10
2026Q4S2026-05-0733050.3248.8052.10
2026Q4S2026-05-0432149.3248.0651.00

Estimate history

EPS, annual-8.3-1.434-1.626-1.066-1.603-2.692-0.754-1.004-2.513-2.3606
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.217-0.302-0.53-0.772-0.728-0.494-0.373-1.038-0.456
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual22.87437.63256.73486.377110.556105.522122.368137.421138.897148.15
Period201720182019202020212022202320242025TTM
Sales, quarterly35.81335.16130.33324.47640.23343.85536.41532.90634.974
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.70722.36928.11231.79736.76837.09438.01438.57346.74447.451
Period201720182019202020212022202320242025MRQ
Shares, quarterly38.47538.57338.80138.87346.68346.74447.06147.13547.451
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue148.15138.90137.42122.37105.52110.5686.3856.7337.63
Cost of Goods Sold Incl. D&A86.3773.9454.3251.8661.5750.8340.3029.9020.28
Gross Profit61.7864.9683.1070.5143.9559.7346.0826.8417.35
Selling, General and Administrative Excl. Other152.00152.37135.72115.17118.66118.3177.6766.5448.80
Research and Development31.3130.8231.0826.0626.8127.9820.1716.1915.80
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-90.22-87.42-52.62-44.66-74.71-58.59-31.58-39.70-31.45
Interest Expense0.000.00---0.400.27--
Unusual Expense45.2133.580.001.3329.560.000.001.900.10
Net Income Before Taxes-110.61-112.27-38.10-27.64-99.41-57.72-31.91-40.98-31.51
Income Taxes0.57-5.120.430.720.16-0.04-0.38-0.190.03
Consolidated Net Income-111.18-107.15-38.53-28.35-99.57-57.69-31.53-40.80-31.54
Net Income From Continuing Operations-111.18-107.15-38.53-28.35-99.57-57.69-31.53-40.80-31.54
Net Income-111.18-107.15-38.53-28.35-99.57-57.69-31.53-40.80-31.54
EPS (Recurring)-1.68-1.96-1.00-0.73-2.13-1.60-1.07-1.57-1.43
EPS (Basic, Before Extraordinaries)-2.36-2.51-1.00-0.75-2.69-1.60-1.07-1.63-1.43
EPS (Diluted)-2.36-2.51-1.00-0.75-2.69-1.60-1.07-1.63-1.43
EBITDA-62.36-68.49-44.26-32.66-67.17-53.29-27.04-36.69-30.10
Non-Operating Income (Expense)24.828.7214.5218.364.851.26-0.050.620.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.3816.3715.7913.2912.1511.667.374.664.88
Price To Sales Ratio1.191.952.978.404.8613.8115.9310.4510.70
Gross Margin41.7046.7760.4757.6241.6554.0353.3547.3046.10
Operating Margin-60.90-62.94-38.29-36.50-70.80-52.99-36.57-69.98-83.57
Net Margin-75.05-77.14-28.04-23.17-94.36-52.18-36.50-71.91-83.80
Shares Outstanding47.4546.7438.5738.0137.0936.7731.8028.1122.37
Market Capitalization142.83142.83409.511,034.26513.211,548.571,472.57661.99406.45

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue34.9732.9136.4143.8540.2324.4830.3335.16
Cost of Goods Sold Incl. D&A21.4720.2320.8523.8223.0313.1810.3412.99
Gross Profit13.5012.6715.5720.0417.2111.3019.9922.17
Selling, General and Administrative Excl. Other35.8335.1737.0943.9147.3640.7342.7836.94
Research and Development7.377.827.328.808.019.0810.048.07
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.32-22.50-21.53-23.87-30.15-29.43-22.79-14.77
Interest Expense0.000.000.000.00-0.000.00-
Unusual Expense-0.4227.0118.330.297.123.403.960.00
Net Income Before Taxes-21.30-48.99-17.55-22.77-36.00-30.09-23.42-11.64
Income Taxes0.29-0.05-0.010.34-2.48-0.07-2.91-0.01
Consolidated Net Income-21.59-48.93-17.54-23.12-33.52-30.01-20.50-11.63
Net Income From Continuing Operations-21.59-48.93-17.54-23.12-33.52-30.01-20.50-11.63
Net Income-21.59-48.93-17.54-23.12-33.52-30.01-20.50-11.63
EPS (Recurring)-0.46-0.64-0.10-0.49-0.62-0.71-0.46-0.30
EPS (Basic, Before Extraordinaries)-0.46-1.04-0.37-0.49-0.73-0.77-0.53-0.30
EPS (Diluted)-0.46-1.04-0.37-0.49-0.73-0.77-0.53-0.30
EBITDA-15.06-15.56-15.13-16.62-23.51-27.14-20.04-12.52
Non-Operating Income (Expense)0.600.5222.311.381.272.743.333.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.993.333.583.494.324.244.313.82
Price To Sales Ratio1.191.331.142.141.922.061.862.98
Gross Margin38.6038.5242.7545.6942.7746.1765.9163.05
Operating Margin-63.83-68.37-59.12-54.42-74.94-120.24-75.13-42.00
Net Margin-61.73-148.71-48.17-52.71-83.31-122.62-67.60-33.07
Shares Outstanding47.4547.1347.0646.7446.6838.8738.8038.57
Market Capitalization142.83203.50165.23297.08252.31258.39252.43409.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments118.23289.12321.32338.74396.46181.58109.1644.4379.68
Short Term Receivables29.9732.1425.4119.0223.7917.1810.916.795.60
Inventories54.7632.7726.1216.9622.1914.8610.465.953.57
Other Current Assets9.299.569.236.806.515.982.142.330.40
Total Current Assets212.26363.59382.10381.52448.95219.60132.6659.5089.25
Net Property, Plant & Equipment40.3433.4936.1841.0329.4525.9112.052.921.87
Total Investments and Advances3.343.412.602.602.581.001.031.000.65
Intangible Assets158.164.036.037.5220.1724.1823.663.660.00
Deferred Tax Assets31.935.21-7.774.995.142.22--
Other Assets4.672.011.660.910.380.360.560.540.00
Total Assets450.70411.74428.57433.58506.51276.18172.1767.6191.78
Short Term Debt Incl. Current Port. of LT Debt7.924.764.242.691.438.910.070.005.04
Accounts Payable13.576.955.053.849.216.805.785.113.55
Income Tax Payable1.121.02-------
Other Current Liabilities52.1529.2829.6924.8326.3424.1013.9813.0211.13
Total Current Liabilities74.7642.0138.9831.3536.9839.8019.8318.1219.71
Long Term Debt29.3232.6237.2241.4220.4621.897.597.624.35
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities32.386.01-9.247.027.795.05--
Other Liabilities18.511.072.402.881.100.5811.050.801.85
Total Liabilities154.9781.7078.6175.6565.5670.0643.5226.5525.91
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity295.73330.04349.96357.93440.95206.12128.6641.0665.87
Total Shareholders Equity295.73330.04349.96357.93440.95206.12128.6641.0665.87
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity295.73330.04349.96357.93440.95206.12128.6641.0665.87
Total Liabilities & Stockholders Equity450.70411.74428.57433.58506.51276.18172.1767.6191.78
Book Value Per Share6.338.569.219.6511.996.484.581.843.03
Tangible Book Value Per Share2.948.459.059.4511.445.723.731.673.03
Full-Time Employees450471-370460314248177126
Price to Book Ratio0.651.212.931.383.547.175.169.97-3.43
Return on Assets-24.85-9.17-6.51-21.18-14.74-14.06-34.03-39.57-41.92
Return on Equity-34.25-11.33-8.00-24.93-17.83-18.84-48.07-58.98-68.11
Return on Invested Capital-32.96-10.62-7.32-24.93-12.50-13.83-29.94-64.77-38.48
Quick Ratio2.117.889.1311.6311.545.146.162.954.35
Current Ratio2.848.669.8012.1712.145.526.693.284.53

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-111.19-107.15-38.53-28.35-99.57-57.69-31.53-40.80-31.54
Depreciation27.8618.938.368.296.125.354.563.011.35
Other Funds (Non Cash)58.2119.2113.8016.4140.5416.6211.087.235.04
Funds from Operations-39.28-74.89-16.38-3.66-52.91-35.72-15.89-30.56-25.14
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-16.59-2.35-18.79-15.194.30-12.19-7.474.37-3.58
Cash from Operating Activities-55.87-77.24-35.16-18.85-48.61-47.91-23.36-26.19-28.72
Capital Expenditures-0.16-2.61-3.37-3.84-11.61-13.62-3.93-10.85-1.52
Net Assets From Acquisitions0.00-93.230.000.000.000.000.00-14.53-3.80
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.01
Purchase or Sale of Investments55.43146.07-78.90-144.610.000.000.000.00-0.15
Purchase of Investments-40.77-69.76-295.61-175.610.000.000.000.00-0.15
Sale Or Maturity of Investments96.19215.83216.7131.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.527.283.300.000.00
Cash from Investing Activities55.2750.23-82.27-148.45-11.09-6.34-0.63-25.38-5.45
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.330.743.072.892.31278.5396.31116.251.85
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.02
Sale of Common Pref Stock0.330.743.072.892.31278.5396.31116.251.87
Proceedsfrom Stock Options0.000.000.000.000.00270.7892.29113.430.00
Issuance or Reduction of Debt, Net-0.150.000.000.000.00-7.74-0.07-0.05-1.93
Change in Long Term Debt-0.150.000.000.000.00-7.74-0.07-0.05-1.93
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.150.000.000.000.00-7.74-0.07-0.05-1.93
Net Financing Active Other Cash Flow-1.95-1.45-2.61-0.200.000.000.000.000.00
Other Financing Activities Uses-1.95-1.45-2.61-0.200.000.000.000.000.00
Cash from Financing Activities-1.77-0.710.462.692.31270.8096.24116.20-0.08
Exchange Rate Effect-0.051.57-0.730.30-0.54-0.090.160.12-
Net Change in Cash-2.42-26.14-117.71-164.31-57.93216.4672.4064.75-34.25
Free Cash Flow-56.03-79.85-38.53-22.69-60.23-61.52-27.30-37.03-30.24
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--5.870.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments77.3693.5399.27118.23134.81261.17
Short Term Receivables27.2022.3427.2829.9733.0323.55
Inventories44.8247.6050.9654.7654.9630.14
Other Current Assets8.747.588.229.2910.487.25
Total Current Assets158.12171.05185.72212.26233.28322.12
Net Property, Plant & Equipment32.5035.0537.2340.3444.8731.46
Total Investments and Advances3.353.353.343.344.143.44
Intangible Assets102.41105.78135.87158.16158.6116.33
Deferred Tax Assets---31.93--
Other Assets4.064.394.504.673.252.26
Total Assets300.44319.63366.67450.70444.14375.61
Short Term Debt Incl. Current Port. of LT Debt7.427.817.937.928.415.15
Accounts Payable12.658.898.6613.5710.639.12
Income Tax Payable2.432.021.781.121.470.73
Other Current Liabilities28.6331.6531.5352.1556.8433.19
Total Current Liabilities51.1350.3749.9174.7677.3548.20
Long Term Debt23.9525.5727.4029.3231.7130.38
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---32.38--
Other Liabilities6.016.477.2218.5120.554.57
Total Liabilities81.0982.4284.53154.97129.6183.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity219.35237.21282.14295.73314.53292.46
Total Shareholders Equity219.35237.21282.14295.73314.53292.46
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity219.35237.21282.14295.73314.53292.46
Total Liabilities & Stockholders Equity300.44319.63366.67450.70444.14375.61
Book Value Per Share4.625.036.006.336.747.52
Tangible Book Value Per Share2.462.793.112.943.347.10
Full-Time Employees---450--
Price to Book Ratio0.650.720.560.940.720.82
Return on Assets-29.86-35.42-27.30-24.85-22.37-17.81
Return on Equity-41.65-46.49-34.81-34.25-29.28-22.27
Return on Invested Capital-8.87-18.62-5.67-7.11-9.68-9.30
Quick Ratio2.222.452.702.112.316.06
Current Ratio3.093.403.722.843.026.68

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.59-48.93-17.54-23.12-33.52-30.01
Depreciation7.276.946.407.256.642.29
Other Funds (Non Cash)3.1430.8123.031.236.866.61
Funds from Operations-11.19-11.19-2.08-14.83-25.69-21.11
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.026.07-16.02-1.62-15.5615.46
Cash from Operating Activities-16.20-5.12-18.11-16.44-41.25-5.66
Capital Expenditures-0.07-0.10-0.090.10-0.68-0.78
Net Assets From Acquisitions0.000.000.000.00-84.280.04
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.9813.7625.358.3432.1062.61
Purchase of Investments-8.42-8.240.00-24.10-15.410.00
Sale Or Maturity of Investments16.4022.0025.3532.4447.5262.61
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.9013.6625.268.44-52.8561.88
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.180.000.34-0.190.260.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.180.000.34-0.190.260.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.09-0.09-0.080.11-0.110.00
Change in Long Term Debt-0.09-0.09-0.080.11-0.110.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.09-0.09-0.080.11-0.110.00
Net Financing Active Other Cash Flow-0.04-0.44-1.03-0.44-0.01-0.43
Other Financing Activities Uses-0.04-0.44-1.03-0.44-0.01-0.43
Cash from Financing Activities0.05-0.53-0.77-0.520.15-0.43
Exchange Rate Effect-0.05-0.03-0.040.070.050.59
Net Change in Cash-8.307.996.35-8.45-93.9056.39
Free Cash Flow-16.28-5.21-18.19-16.35-41.93-6.43

Revenue breakdown

Grant2024: 1.99M 2025: 243.00K
License and Service2024: 4.45M 2025: 1.50M
Product2024: 79.74M 2025: 92.94M
Service And Other2024: 51.24M 2025: 44.21M
United States2024: 137.42M 2025: 138.90M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.93%4.6M41.8M745.05K
2026-10-1511.21%4.7M41.8M758.32K
2026-09-3012.08%5.0M41.8M747.59K
2026-09-1511.91%5.0M41.8M907.82K
2026-08-3111.53%4.8M41.8M865.19K
2026-08-1411.33%4.7M41.8M982.48K
2026-07-3110.83%4.5M41.6M1.09M
2026-07-1510.50%4.3M41.3M1.19M
2026-06-3010.47%4.3M41.3M1.26M
2026-06-1511.68%4.5M38.4M1.13M
2026-05-2913.19%5.1M38.4M1.10M
2026-05-1513.43%5.1M38.4M1.00M
2026-04-3011.99%4.6M38.4M799.85K
2026-04-1511.29%4.3M38.1M748.40K
2026-03-3111.31%4.3M38.2M727.16K
2026-03-1310.75%4.1M38.2M659.63K
2026-02-2710.79%4.1M38.2M663.72K
2026-02-1310.29%3.9M38.0M732.03K
2026-01-309.42%3.6M38.0M734.45K
2026-01-158.99%3.4M38.0M698.61K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.150.850.853.25533910.000.749-0.0510.001
call5.000.000.400.054.7052040.000.374-0.0470.002
call7.500.000.100.043.5663080.000.131-0.0210.001
put2.500.000.750.206.0061040.00-0.251-0.0510.001
put5.001.553.202.379.19817.000.00-0.626-0.0470.002
put7.502.406.304.9014.4040.000.00-0.867-0.0230.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-193Initial statement of beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-06SCHEDULE 13GSEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-223Initial statement of beneficial ownership of securities2026-06-22SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08286.35K200
2026-070000
2026-060000
2026-059.70K100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.7.72%
Blue Water Life Science Advisors, LP7.38%
First Eagle Investment Management, LLC4.64%
Portolan Capital Management, LLC4.03%
VANGUARD CAPITAL MANAGEMENT LLC3.82%
Lionhunter Capital Management, LLC3.19%
AQR CAPITAL MANAGEMENT LLC2.85%
GEODE CAPITAL MANAGEMENT, LLC2.40%
AMERIPRISE FINANCIAL INC2.10%
MARSHALL WACE, LLP2.07%

Funds

Fund% owned
First Eagle Small Cap Opportunity Fund5.80%
Strategic Advisers U.S. Total Stock Fund3.05%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.66%
iShares Russell 2000 ETF2.39%
Invenomic Fund1.64%
Columbia Small Cap Value Discovery Fund1.46%
VANGUARD EXTENDED MARKET INDEX FUND1.02%
Fidelity Small Cap Index Fund0.99%
iShares Russell 2000 Value ETF0.83%
iShares Biotechnology ETF0.60%

OakChart. QTRX. Cached 15 minutes.